Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603121 · ClinicalTrials.gov registry record · Phase 1
Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus
A Phase 1 study, sponsored by Eastern Virginia Medical School.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01603121 is a Phase 1 study that was terminated before completion, run by Eastern Virginia Medical School. The registered enrollment target is 1 participants.
The verdict
NCT01603121, a Phase 1 study, was terminated before completion, sponsored by Eastern Virginia Medical School.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary goal of the study is to investigate the safety and tolerability of the investigational drug lisofylline, when administered under the skin or in the vein, in people with type 1 diabetes. A second aim is to determine how much drug is available in the blood after injection under the skin, compared to injection in the vein.
Interventions
- DRUG Lisofylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603121
The ClinicalTrials.gov registry entry for NCT01603121 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lisofylline is the first listed.
NCT01603121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01603121 about?
NCT01603121 is a clinical study titled "Lisofylline as Continuous Subcutaneous and Intravenous Administration in Subjects With Type 1 Diabetes Mellitus". The primary goal of the study is to investigate the safety and tolerability of the investigational drug lisofylline, when administered under the skin or in the vein, in people with type 1 diabetes. A second aim is to determine how much drug is available in the blood after injection under the skin, c...
What is the current status of trial NCT01603121?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01603121?
The interventions under investigation include: Lisofylline (DRUG).
Who is sponsoring clinical trial NCT01603121?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.